Diabetes Care

Papers
(The H4-Index of Diabetes Care is 89. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
About the Artist: Laura Jacobsen, MD1897
Issues and Events1762
In This Issue of Diabetes Care1180
The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)1051
Comment on Maddaloni et al. Bone-Vascular Axis Biomarkers: Enhancing Cardiovascular Risk Management in Type 2 Diabetes681
Interoceptive Awareness Is Associated With Impaired Awareness of Hypoglycemia in Adults With Type 1 Diabetes665
Response to Comment on Huh et al. Remnant Cholesterol Is an Independent Predictor of Type 2 Diabetes: A Nationwide Population-Based Cohort Study. Diabetes Care 2023;46:305–312642
Comment on Gyldenkerne et al. Negative Trend in Peripheral Artery Disease in Incident Type 2 Diabetes in Germany557
Response to Comment on Meek et al. Reappearance of C-Peptide During the Third Trimester in Type 1 Diabetes Pregnancy: Pancreatic Regeneration or Fetal Hyperinsulinism? Diabetes Care 2021;44:1826–1834524
Response to Comments on Maddaloni et al. Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. Diabetes Care 2025;48:235–242516
About the Artist: Abby Gregg465
Predictors of Diabetes Outcomes at 1 Year After Islet Autotransplantation: Data From a Multicenter Cohort Study427
Refining the Definition of Stage 1 Type 1 Diabetes: An Ontology-Driven Analysis of the Heterogeneity of Multiple Islet Autoimmunity356
Disclosures: Standards of Care in Diabetes—2025346
The Portfolio Diet and Incident Type 2 Diabetes: Findings From the Women’s Health Initiative Prospective Cohort Study336
Associations of Dietary Cholesterol Consumption With Incident Diabetes and Cardiovascular Disease: The Role of Genetic Variability in Cholesterol Absorption and Disease Predisposition336
Plasma Tryptophan-Kynurenine Pathway Metabolites and Risk for Progression to End-Stage Kidney Disease in Patients With Type 2 Diabetes319
Natural Language Processing for Automated Extraction of Continuous Glucose Monitoring Data299
An Integrated Digital Health Care Platform for Diabetes Management With AI-Based Dietary Management: 48-Week Results From a Randomized Controlled Trial280
Prevalence of Chronic Kidney Disease in Type 1 Diabetes Among Adults in the U.S.271
Associations Between Glucose Metabolism Measures and Amyloid-β and Tau Load on PET 14 Years Later: Findings From the Framingham Heart Study258
15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024238
Proinsulin–to–C-Peptide Ratio as a Marker of β-Cell Function in African American and European American Adults233
Arterial Stiffness, Genetic Risk, and Type 2 Diabetes: A Prospective Cohort Study225
Beliefs Around Hypoglycemia and Their Impacts on Hypoglycemia Outcomes in Individuals with Type 1 Diabetes and High Risks for Hypoglycemia Despite Using Advanced Diabetes Technologies224
Personalizing Physical Activity for Glucose Control Among Individuals With Type 2 Diabetes: Are We There Yet?216
Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level214
Neuropathic Pain With and Without Diabetic Peripheral Neuropathy in Type 1 Diabetes209
Urgent Need for Standardization in CGM Performance Assessment204
Demographic, Clinical, Management, and Outcome Characteristics of 8,004 Young Children With Type 1 Diabetes204
Physical Activity Support Can Improve Outcomes in Youth With Type 1 Diabetes203
Risks of Tight Glucose Control in Older Adults: Time to Focus Beyond Mortality201
Glucagon Prescribing and Costs Among U.S. Adults With Diabetes, 2011–2021197
Real-time Continuous Glucose Monitoring in the Intensive Care Unit: The Fifth Vital Sign192
Physical Activity for Type 2 Diabetes Prevention: Some Is Better Than None, More Is Better, and Earliest Is Best190
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial184
Comparison of Insulin Titration Strategies for Glycemic Control in Type 2 Diabetes: A Systematic Review and Network Meta-analysis173
About the Artists: John B. Buse, MD, PhD, and Mary Beth Cassely, MSPH173
Trends in Metformin Use Among Patients With Prediabetes: 2008–2020172
Severe Mental Illness and Type 2 Diabetes Outcomes and Complications: A Nationwide Cohort Study170
Diet-Related Lipidomic Signatures and Changed Type 2 Diabetes Risk in a Randomized Controlled Feeding Study With Mediterranean Diet and Traditional Chinese or Transitional Diets165
The Effectiveness of Shared Decision-making for Diabetes Prevention: 24- and 36-Month Results From the Prediabetes Informed Decision and Education (PRIDE) Trial163
12. Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes—2022162
Disparities in Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Prescription and Dispensing in the Israeli Population—A Retrospective Cohort Study158
Persistence of Risk for Type 2 Diabetes After Gestational Diabetes Mellitus156
Issues and Events155
Socioeconomic Factors Play a More Important Role than Clinical Needs in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in People With Type 2 Diabetes155
Issues and Events153
Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)150
Issues and Events150
Health-Related Quality of Life and Health Utility After Metabolic/Bariatric Surgery Versus Medical/Lifestyle Intervention in Individuals With Type 2 Diabetes and Obesity: The ARMMS-T2D Study149
Quantifying Environmental Waste From Diabetes Devices in the U.S.145
About the Artist: Giorgio Baldini143
Phenotype and Lifestyle Intervention: Potential for Predicting and Improving Metabolic Outcomes?139
Disruption to Pattern but No Overall Increase in the Expected Incidence of Pediatric Diabetes During the First Three Years of the COVID-19 Pandemic in Ontario, Canada (March 2020–March 2023)139
Is Son Preference a Potential Risk Factor for Diabetes?139
Physical Activity Is Associated With Improved Glycemic Outcomes in Newly Diagnosed Youth With Type 1 Diabetes: 4T Exercise Program135
Rational Pharmacotherapy in Type 2 Diabetes: Danish Data From 2002 to 2020 on Mortality, Diabetes- Related Outcomes, Adverse Events, and Medication Expenses134
Effectiveness of Low Intensity Mental Health Support via a Telehealth Enabled Network (LISTEN) for Adults With Diabetes Distress: A Parallel Group, Pragmatic Randomized Controlled Trial132
Clinical Prediction Models Combining Routine Clinical Measures Have High Accuracy in Identifying Youth-Onset Type 2 Diabetes Defined by Maintained Endogenous Insulin Secretion: The SEARCH for Diabetes124
Health and Economic Impact and Cost-effectiveness of Produce Prescriptions for Diabetes in 50 U.S. States: A Microsimulation Study122
Plasma Metabolome, Long-term Body Weight Change, and Type 2 Diabetes in U.S. Individuals119
Predictive Value of C-Peptide Measures for Clinical Outcomes of β-Cell Replacement Therapy in Type 1 Diabetes: Report From the Collaborative Islet Transplant Registry (CITR)117
Genetic Discovery and Risk Prediction for Type 1 Diabetes in Individuals Without High-Risk HLA-DR3/DR4 Haplotypes117
Comment on Hamblin et al. Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor–Treated Type 2 Diabetes. Diabetes Care 2021;44:e124–116
Response to Comment on Fahrmann et al. Modification of the Association Between Severe Hypoglycemia and Ischemic Heart Disease by Surrogates of Vascular Damage Severity in Type 1 Diabetes During ∼30 Ye114
Trends in Racial and Ethnic Disparities in Early Glycemic Control Among Veterans Receiving Care in the Veterans Health Administration, 2008–2019113
Response to Comment on Seidu et al. Efficacy and Safety of Continuous Glucose Monitoring and Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: A Systematic Review 112
COVID-19–Related Multisystem Inflammatory Syndrome in Children Presenting With New-Onset Type 1 Diabetes in Severe Ketoacidosis: A Case Series108
Effect of a Mobile Health Technology–Based Diabetes Education Program on Glucose Control in Patients With Type 2 Diabetes Initiating Premixed Insulin: A Prospective, Multicenter, Observational Study108
Islet Transplantation Versus Standard of Care for Type 1 Diabetes Complicated by Severe Hypoglycemia From the Collaborative Islet Transplant Registry and the T1D Exchange Registry106
COVID-19 Vaccination Prior to SARS-CoV-2 Infection Reduced Risk of Subsequent Diabetes Mellitus: A Real-World Investigation Using U.S. Electronic Health Records106
Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384–390105
Community-Based Peer Support for Diabetes Management: 24-Month Changes Relative to Comparison Communities105
Estimating Glycemia From HbA1c and CGM: Analysis of Accuracy and Sources of Discrepancy105
Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment103
Diabetic Ketoacidosis at Onset of Type 1 Diabetes and Long-term HbA1c in 7,961 Children and Young Adults in the Australasian Diabetes Data Network102
Progression of Cerebral Small Vessel Disease Among Neurologically Asymptomatic Middle-Aged Individuals With Type 1 Diabetes102
Prevalence and Predictors of Household Food Insecurity and Supplemental Nutrition Assistance Program Use in Youth and Young Adults With Diabetes: The SEARCH for Diabetes in Youth Study99
Twenty-Year Temporal Trends in Risk of Ischemic Stroke in Incident Type 2 Diabetes: A Danish Population-Based Cohort Study98
The Broader Economic Value of Treatment for Diabetic Macular Edema98
Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE96
Use of a Dual GIP/GLP-1 Receptor Agonist in HNF1A-MODY and HNF4A-MODY96
The Glycemic Impact of Protein Ingestion in People With Type 1 Diabetes96
Leisure-Time Physical Activity May Attenuate the Impact of Diabetes on Cognitive Decline in Middle-Aged and Older Adults: Findings From the ELSA-Brasil Study96
Large-Scale Proteomics Improve Risk Prediction for Type 2 Diabetes94
Large Language Model GPT-4 Compared to Endocrinologist Responses on Initial Choice of Glucose-Lowering Medication Under Conditions of Clinical Uncertainty93
Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study91
Influence of Gestational Diabetes Mellitus on Diabetes Risk and Glycemic Control in a Retrospective Population-Based Cohort89
0.20029616355896